MX2020005442A - FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. - Google Patents

FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.

Info

Publication number
MX2020005442A
MX2020005442A MX2020005442A MX2020005442A MX2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A MX 2020005442 A MX2020005442 A MX 2020005442A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
hydroxyandrostan
ethynyl
oxime
optionally
Prior art date
Application number
MX2020005442A
Other languages
English (en)
Inventor
Magnus Doverskog
Paul Alhadeff
Maja Johansson
Thomas Meijer
Nicolaas Schipper
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of MX2020005442A publication Critical patent/MX2020005442A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención está dirigida a una formulación farmacéutica novedosa que comprende 3a-etinil-3ß-hidroxiandrostan- 17-ona oxima en una cantidad de 0.1-10% en peso del peso total de la composición; y un vehículo que comprende (a) 45-100% de un monoéster; (b) opcionalmente hasta 51% de un diéster; y (c) opcionalmente hasta aproximadamente 10% de un triéster. También se reclama un método para el tratamiento de condiciones médicas como hipersomnia y encefalopatía hepática mediante el uso de una formulación farmacéutica como se reclama.
MX2020005442A 2017-11-27 2018-11-27 FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA. MX2020005442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590757P 2017-11-27 2017-11-27
PCT/EP2018/082727 WO2019102040A1 (en) 2017-11-27 2018-11-27 PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME

Publications (1)

Publication Number Publication Date
MX2020005442A true MX2020005442A (es) 2022-03-30

Family

ID=64556898

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005442A MX2020005442A (es) 2017-11-27 2018-11-27 FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.

Country Status (11)

Country Link
US (2) US10603326B2 (es)
EP (1) EP3716954A1 (es)
JP (1) JP7314459B2 (es)
KR (1) KR20200093008A (es)
CN (1) CN111432805B (es)
AU (1) AU2018374029B2 (es)
BR (1) BR112020010519A2 (es)
CA (1) CA3083555A1 (es)
IL (1) IL274893B1 (es)
MX (1) MX2020005442A (es)
WO (1) WO2019102040A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432805B (zh) 2017-11-27 2023-02-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US20040191207A1 (en) 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
WO2008030389A2 (en) 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
PL2097437T3 (pl) 2006-11-21 2015-12-31 Umecrine Cognition Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN
CN102753181B (zh) 2010-01-14 2014-09-17 优麦克里尼穆德公司 具有改进的储存特性和溶解度特性的包含3-β-羟基-5-α-孕烷-20-酮的药物组合物
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
AR096459A1 (es) 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
JP6543633B2 (ja) * 2014-01-29 2019-07-10 ウメクライン コグニション アーベー 肝性脳症の治療において使用するためのステロイド化合物
BR112016028192A2 (pt) 2014-06-17 2017-08-22 Merck Sharp & Dohme gerritdina g. schoonus-gerritsma
US9498485B2 (en) * 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
KR101679992B1 (ko) 2015-12-31 2016-11-28 주식회사 유유제약 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법
KR101716878B1 (ko) 2016-05-12 2017-03-15 주식회사 유유제약 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
CN111432805B (zh) 2017-11-27 2023-02-17 梅克里内科尼蒂翁公司 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂

Also Published As

Publication number Publication date
CA3083555A1 (en) 2019-05-31
US20200297737A1 (en) 2020-09-24
AU2018374029A1 (en) 2020-06-18
CN111432805B (zh) 2023-02-17
WO2019102040A1 (en) 2019-05-31
RU2020121142A3 (es) 2022-03-28
IL274893A (en) 2020-07-30
BR112020010519A2 (pt) 2020-10-20
JP2021504468A (ja) 2021-02-15
JP7314459B2 (ja) 2023-07-26
CN111432805A (zh) 2020-07-17
IL274893B1 (en) 2024-04-01
KR20200093008A (ko) 2020-08-04
EP3716954A1 (en) 2020-10-07
US10603326B2 (en) 2020-03-31
AU2018374029B2 (en) 2024-01-11
RU2020121142A (ru) 2021-12-29
US11123351B2 (en) 2021-09-21
US20190358244A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
NZ708593A (en) Novel pyrazole derivative
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2017013556A (es) Compuestos novedosos.
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX368387B (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
MX2019007571A (es) Polimorfos.
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX352386B (es) Nuevos derivados quinona de cannabidiol.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
MX367404B (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX2020005442A (es) FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
BR112019008239A2 (pt) formulações aquosas, estáveis, injetáveis de capsaicina e uso médicos dos mesmos
MY183540A (en) Injectable buprenorphine formulation
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
PH12020550947A1 (en) Polymorphs
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EP3643302C0 (en) COMPOSITION WITH SESQUITERPENDERIVATE AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF MUSCLE DISEASES
MX2019012522A (es) Compuestos y metodos terapeuticos.